Therefore, it is essential to integrate multi-omics data (genome, transcriptome, epigenome, metabolome and immunome) to comprehensively understand the molecular network and to refine the molecular stratification of KRAS-mutant CRC, which may help to develop combination therapies that are more suitable for KRAS-mutant CRC. This evidence concerns the gene KRAS and colorectal carcinoma.